1974 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 13 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
alvocidib Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
tipifarnib Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1974 2018

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C., Rosner, G., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I., Beumer, J. H., Pratz, K., McDevitt, M. A., Baer, M. R., Blackford, A. L., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M., Levis, M. J., Dezern, A., Gladstone, D., Ji, J. J., Wang, L., Kinders, R. J., Pouquet, M., Ali-Walbi, I., Rudek-Renaut, M., Poh, W. & 5 othersHerman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J., Feb 1 2017, In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

temozolomide
Acute Myeloid Leukemia
Methylation
Phosphorylation
Polymers

A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

Pratz, K., Rudek-Renaut, M., Gojo, I., Litzow, M. R., McDevitt, M. A., Ji, J., Karnitz, L. M., Herman, J. G., Kinders, R. J., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M., Gladstone, D., Levis, M. J., Tsai, H. L., Rosner, G., Chen, A., Kaufmann, S. H. & Karp, J., Feb 15 2017, In : Clinical Cancer Research. 23, 4, p. 899-907 9 p.

Research output: Contribution to journalArticle

Leukemia, Myelomonocytic, Chronic
Topotecan
Carboplatin
Leukemia
Neoplasms

Assessment of drug sensitivity in hematopoietic stem and progenitor cells from acute myelogenous leukemia and myelodysplastic syndrome ex vivo

Knorr, K. L. B., Finn, L. E., Smith, B. D., Hess, A. D., Foran, J. M., Karp, J. & Kaufmann, S. H., Mar 1 2017, In : Stem cells translational medicine. 6, 3, p. 840-850 11 p.

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Myeloid Progenitor Cells
Stem Cells
L-Lactate Dehydrogenase
Tumor Microenvironment
Lactic Acid
Clone Cells
Biomarkers